News & Alerts
-
Dec- 2023 -13 December
Acesion Pharma’s Breakthrough in Atrial Fibrillation Treatment Published in Nature Medicine
In a groundbreaking development in the field of cardiac arrhythmia, Acesion Pharma, a biotech company specializing in novel therapies for…
Read More » -
12 December
Cipla Initiates Voluntary Recall of Vigabatrin for Oral Solution Due to Seal Integrity Issues
Cipla Limited, a global pharmaceutical company, has announced the voluntary recall of one lot of Vigabatrin for Oral Solution, USP…
Read More » -
12 December
Global Gene Therapy Market Expected to Surge by USD 4,613.9 Million from 2022 to 2027
The global gene therapy market is anticipated to witness substantial growth, with Technavio projecting a robust increase of USD 4,613.9…
Read More » -
12 December
Scinai’s Aerosolized NanoAbs: Promising COVID-19 Prophylactic and Therapeutic, Study Finds
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products, has announced the publication…
Read More » -
12 December
Federal Judge Allows Lawsuit Over Ozempic Side Effects to Proceed
In a recent development, a federal judge in Louisiana has ruled against Novo Nordisk’s attempt to dismiss one of the…
Read More » -
12 December
Disappointment As Study Reveals Weight Regain in Patients After Discontinuation of Eli Lilly’s Zepbound
In a significant development, the full results of a study published in the journal JAMA on Monday have unveiled that…
Read More » -
12 December
Myanmar Emerges as World’s Largest Opium Source Amid Afghan Decline, UN Reports
In a startling revelation, Myanmar has now claimed the dubious distinction of being the world’s largest source of opium, surpassing…
Read More » -
11 December
Shuttle Pharma Submits Ropidoxuridine IND for Glioblastoma Treatment to FDA
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) has announced a significant stride in its mission to address glioblastoma, a…
Read More » -
11 December
Global H1N1 Vaccines Market Thrives: Intramuscular Segment and Hospital Pharmacies at the Forefront
A recent report by Research and Markets forecasts significant growth in the Global H1N1 Vaccines Market until 2028. This comprehensive…
Read More » -
11 December
Novartis Reports Positive 48-Week Results for Fabhalta in PNH Trial
Novartis Pharmaceuticals Corporation has released new 48-week results from the Phase III APPLY-PNH trial, showcasing sustained efficacy and long-term safety…
Read More »